These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 37476900)

  • 1. Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
    Vural E; Engin E; Sünter G; Yıldırım KA; Günal D
    Turk J Med Sci; 2023 Jun; 53(3):771-779. PubMed ID: 37476900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of ozanimod
    Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M
    Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.
    Prosperini L; Lucchini M; Haggiag S; Bellantonio P; Bianco A; Buscarinu MC; Buttari F; Centonze D; Cortese A; De Giglio L; Fantozzi R; Ferraro E; Fornasiero A; Francia A; Galgani S; Gasperini C; Marfia GA; Millefiorini E; Nociti V; Pontecorvo S; Pozzilli C; Ruggieri S; Salvetti M; Sgarlata E; Mirabella M
    Neurology; 2018 Jul; 91(2):e153-e161. PubMed ID: 29875218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life persistence and tolerability with dimethyl fumarate.
    Sejbaek T; Nybo M; Petersen T; Illes Z
    Mult Scler Relat Disord; 2018 Aug; 24():42-46. PubMed ID: 29906666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Patient and Clinician Assessment of Gastrointestinal (GI) Related Adverse Events Associated with Oral Disease-Modifying Therapies in Multiple Sclerosis: A Qualitative Study.
    Jivraj F; Kang S; Reedie S; Kapadia S; Strzok S; Elliott E; Cano S; Rock M
    Adv Ther; 2022 Nov; 39(11):5072-5086. PubMed ID: 36053450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
    Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
    Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H; Niino M; Onizuka Y; Hiramatsu K; Hase M; Yun J; Matta A; Torii S
    Adv Ther; 2018 Oct; 35(10):1598-1611. PubMed ID: 30206820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
    Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
    Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
    Freedman MS; Montalban X; Miller AE; Dive-Pouletty C; Hass S; Thangavelu K; Leist TP
    Mult Scler Relat Disord; 2016 Nov; 10():204-212. PubMed ID: 27919491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population.
    Sabin J; Urtiaga S; Pilo B; Thuissard I; Galan V; Sainz de la Maza S; Costa-Frossard L; Gómez-Moreno M; Díaz-Díaz J; Oreja-Guevara C; Martínez-Ginés ML; Lozano A; Borrega L; Ayuso L; Castro A; Sanchez P; Meca-Lallana V; Muñoz C; Casanova I; López de Silanes C; Martín H; Rodriguez-García E; Moreno I; García-Merino JA; Aladro Y;
    J Neurol; 2020 Aug; 267(8):2362-2371. PubMed ID: 32350647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
    Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
    Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
    Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
    Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.
    Wray S; Then Bergh F; Wundes A; Arnold DL; Drulovic J; Jasinska E; Bowen JD; Negroski D; Naismith RT; Hunter SF; Gudesblatt M; Chen H; Lyons J; Shankar SL; Kapadia S; Mendoza JP; Singer BA
    Adv Ther; 2022 Apr; 39(4):1810-1831. PubMed ID: 35211872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.